Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Doxycycline · Doxycycline Monohydrate

Small molecule · Inhibitor of bacterial 30S ribosomal subunit · developed by Chartwell Rx

Approved FDA, Dec 1989
1 Registered trials

What is Doxycycline?

Doxycycline is a tetracycline-class antibiotic that reversibly binds the bacterial 30S ribosomal subunit and inhibits bacterial protein synthesis. An extended-release formulation (D-PLEX) is studied for preventing surgical site infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Doxycycline Monohydrate, D-PLEX
Drug type
Small molecule
Targets
bacterial 30S ribosomal subunit
Mechanism
Inhibitor of bacterial 30S ribosomal subunit
Pathways
bacterial protein synthesis inhibition
Therapy area
Infectious disease
Developer
Chartwell Rx
In trials of
PYPD
FDA status
Approved as Doxycycline Monohydrate (December 29, 1989), NDA050641 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 15, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04411199 Phase 3 Surgical Site Infection Completed PYPD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Abdominal SurgeryColon SurgeryPost-Op InfectionSurgical Site Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.